<DOC>
	<DOCNO>NCT01912053</DOCNO>
	<brief_summary>The purpose study assess efficacy tolerance intra-hepatic administration Yttrium 90-labelled microsphere ( Theraspheres® , Nordion ) association intravenous chemotherapy Gemcitabin Cisplatin treatment intra-hepatic cholangiocarcinoma .</brief_summary>
	<brief_title>Efficacy Study Intra-hepatic Administration Therasphere® Association With Intravenous Chemotherapy Treat Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Histologically confirm intrahepatic cholangiocarcinoma . 2 . Measurable target least 2 cm diameter . 3 . Healthy liver cirrhosis CHILD &lt; B8 . 4 . WHOPS : 01 . 5 . Age ≥ 18 year . 6 . NonMetastatic disease extrahepatic ( permit : local lymph node &lt; 3 cm , less 5 lung node &lt; 11 mm ) . 7 . Creatinine clearance ( calculate Cockcroft Gault formula ) ≥ 55 ml/min , polymorphonuclear neutrophil ≥ 1500 G/L , platelets ≥ 80 G/L , prothrombin ≥ 40 % ( INR ≤ 2.3 ) , serum albumin ≥ 28 g/l , serum bilirubin ≤ 3 x LSN . 8 . Pregnancy test : negative woman childbearing potential . 9 . Reliable contraception childbearing couple , men woman must reliable contraception treatment 6 month follow end treatment chemotherapy 10 . Signed informed consent form . 11 . Patient national health insurance . 1 . Pancreas cancer duodenum cancer invade bile duct ampullary cancer . Cholangiocarcinoma bile duct : hilar , main duct , gallbladder . 2 . Extrahepatic metastasis ( include local lymph node measure &gt; 30 mm ) . 3 . Primary sclerosing cholangitis . 4 . History chemoembolization radioembolization . 5 . Cirrhose CHILD &gt; B7 6 . Portal vein trunk tumoral thrombosis 7 . History hepatobiliary neo adjuvant palliative chemotherapy and/or radiotherapy . 8 . Contra indication Gemcitabine and/or Cisplatin . 9 . Other invasive active cancer , except situ cervical cancer basocellular spino cellular skin cancer treat adequately . Any history cancer consider completely cure least one year . 10 . Technical failure diagnostic arteriography . 11 . Extra hepatic uptake pretherapeutic scintigraphy manageable arteriography . 12 . Dosimetry study predict lung exposure &gt; 30 Gy . 13 . Any unstable medical history ( diabetes , hypertension … ) . 14 . History organ transplant . 15 . Symptomatic grade 1 angina pectoris grade ≥ 2 angina pectoris . 16 . An evolutive neuropathy . 17 . Patient already involve clinical trial drug intake , whether drug experimental , within 30 day . 18 . Pregnant patient patient breastfeeding . 19 . Patient administrative supervision . 20 . Regular followup impossible various reason ( psychological , familial , economical , social ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Intra-hepatic Cholangiocarcinoma treatment</keyword>
</DOC>